Clinical Trials
Glioblastoma Remission Rates Remain Challenging Despite Treatment Advances
Only 25% of glioblastoma patients experience remission lasting at least two years, highlighting the urgent need for improved treatments for this aggressive brain cancer.
Lantern Pharma Reports Complete Response in AI-Driven Cancer Drug Trial
Lantern Pharma's AI-developed drug LP-284 achieved a complete metabolic response in a heavily pre-treated lymphoma patient, demonstrating the potential of artificial intelligence to accelerate oncology drug development and address critical treatment gaps.
New IDSA Guidelines Highlight Critical Need for Tailored COVID-19 Vaccines for Immunocompromised Population
GeoVax's GEO-CM04S1 vaccine addresses the significant protection gap for over 40 million immunocompromised Americans who experience limited effectiveness from current COVID-19 vaccines, as highlighted by new Infectious Diseases Society of America guidelines.
Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic
Aditxt's subsidiary Pearsanta has begun enrolling patients in a clinical study for a novel blood-based endometriosis test that could provide earlier, non-invasive detection compared to current surgical methods.
NanoViricides to Present Antiviral Pipeline Updates at PODD 2025 Conference
NanoViricides will showcase its broad-spectrum antiviral drug platform at the upcoming PODD 2025 conference, highlighting progress toward Phase II trials for its lead candidate NV-387 targeting multiple respiratory viruses and MPox.
Annovis Bio Secures $3.4 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies
Annovis Bio has raised $3.4 million through a registered direct offering to fund development of treatments for Alzheimer's and Parkinson's diseases, providing crucial capital for advancing late-stage clinical programs targeting neurodegeneration.
Soligenix's HyBryte Shows Promise as Potential First-Line Treatment for Cutaneous T-Cell Lymphoma
Soligenix Inc. is advancing HyBryte as a potential first-line therapy for early-stage cutaneous T-cell lymphoma following promising results from clinical trials that could reshape treatment standards in the rare disease space.
Pentixapharm Restructures Operations with 50% Workforce Reduction to Focus on Advanced Clinical Programs
Pentixapharm Holding AG is implementing significant organizational changes including a 50% workforce reduction and reduced early-stage research to concentrate resources on its most advanced clinical development programs, particularly the Phase 3-ready CXCR4 program for treatment-resistant hypertension diagnosis.
Oncotelic Therapeutics Announces Three Abstracts on Deciparticle Everolimus Accepted for 2025 San Antonio Breast Cancer Symposium
Oncotelic Therapeutics will present three abstracts on its investigational intravenous Deciparticle everolimus at the 2025 San Antonio Breast Cancer Symposium, highlighting potential improvements over existing mTOR inhibitors for metastatic breast cancer treatment.
Study Finds mRNA COVID Vaccine May Enhance Cancer Immunotherapy Effectiveness
New research presented at the European Society for Medical Oncology conference suggests mRNA coronavirus vaccines could potentially boost the effectiveness of cancer immunotherapy treatments.
Oncotelic's 20nm Nanoparticle Technology Enters Human Trials for Enhanced Breast Cancer Treatment
Oncotelic Therapeutics has begun human trials for its 20nm nanoparticle formulation of Everolimus, representing a significant advancement in cancer drug delivery that could dramatically improve tumor targeting and treatment efficacy.
Oragenics Regains NYSE Compliance Following $16.5 Million Funding Round for Concussion Treatment Development
Oragenics Inc. has regained full compliance with NYSE American listing standards following a successful $16.5 million public offering, securing financial stability to advance its intranasal concussion treatment through critical clinical trials.
Kairos Pharma Reports Positive Interim Phase 2 Results for ENV-105 in Advanced Prostate Cancer
Kairos Pharma announced positive interim Phase 2 data showing ENV-105 combined with apalutamide achieved clinical benefit in 86% of metastatic castration-resistant prostate cancer patients, potentially addressing treatment resistance in advanced disease.
Annovis Bio Secures $6 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies
Annovis Bio has closed a $6 million registered direct offering to fund development of treatments for Alzheimer's and Parkinson's diseases, providing crucial capital for advancing late-stage clinical programs targeting neurodegeneration.
GeoVax Reports Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients
GeoVax Labs announced promising Phase 2 clinical trial results showing its multi-antigen COVID-19 vaccine candidate demonstrates strong safety and robust T-cell responses in immunocompromised patients, potentially addressing a critical gap in protection for vulnerable populations.
NanoViricides' Dual-Track Clinical Strategy for NV-387 Antiviral Drug Highlighted in Analyst Report
NanoViricides is advancing its broad-spectrum antiviral drug candidate NV-387 through a dual-track clinical development strategy targeting both MPox and respiratory viral infections, with potential implications for global pandemic preparedness and biodefense funding opportunities.
Alpha Cognition to Present at Spartan Capital Investor Conference, Highlighting Neurodegenerative Disease Treatments
Alpha Cognition's participation in the Spartan Capital Securities investor conference provides a platform to showcase its innovative treatments for Alzheimer's and cognitive impairment from traumatic brain injury, potentially attracting crucial investment for addressing unmet medical needs.
Lantern Pharma Advances Rare Pediatric Brain Cancer Treatment Using AI Platform
Lantern Pharma is preparing clinical trials for a rare pediatric brain cancer treatment using its AI-powered RADR platform, following positive FDA feedback on trial design and regulatory pathways.
TransCode Therapeutics Advances Cancer Treatment with Successful Phase 1a Trial of TTX-MC138
TransCode Therapeutics has successfully completed Phase 1a clinical trials for TTX-MC138, an RNA-based cancer treatment targeting metastatic disease, showing promising safety results and disease stabilization in nearly half of patients, advancing to Phase 2 evaluation.
Soligenix Strengthens Medical Advisory Board to Advance HyBryte CTCL Treatment Through Phase 3 Development
Soligenix has updated its U.S. Medical Advisory Board with leading dermatologic and oncologic experts to guide the Phase 3 development and potential commercialization of HyBryte, a novel photodynamic therapy for cutaneous T-cell lymphoma that addresses significant unmet medical needs.
Soligenix Secures $7.5 Million in Public Offering to Advance Rare Disease Pipeline Through 2026
Soligenix has closed a $7.5 million public offering that extends its financial runway through 2026, enabling continued advancement of its rare disease treatment pipeline including late-stage clinical trials and regulatory milestones.
GeoVax Executives Pursue European Partnerships to Advance Vaccine and Cancer Therapy Development
GeoVax Labs is intensifying European partnership efforts to accelerate development of vaccines for mpox, COVID-19, and cancer therapies, addressing critical global health needs.
Neutra Life Sciences Expands Clinical Research Network with New Family Medicine Partnership
Neutra Corp's subsidiary has expanded its clinical trial site network through a joint venture with MediNet Family Care Clinic, strengthening its position in community-based research for chronic conditions while enhancing investor communication.
Lifordi Immunotherapeutics Reports Promising Preclinical Data for Autoimmune Treatment LFD-200
Lifordi Immunotherapeutics will present new preclinical data showing its antibody drug conjugate LFD-200 delivers glucocorticoids directly to immune cells with sustained anti-inflammatory effects and no systemic toxicity, potentially offering a safer treatment option for autoimmune diseases.
Soligenix Expands European Medical Advisory Board to Advance CTCL Treatment Development
Soligenix is strengthening its European medical advisory board and advancing Phase 3 clinical trials for HyBryte, a potential new treatment for cutaneous T-cell lymphoma that addresses significant unmet medical needs in European patients.
Annovis Bio Reports Buntanetap Shows Promising Biomarker Improvements in Alzheimer's Patients
Annovis Bio's buntanetap demonstrated significant reductions in inflammatory biomarkers and improved neuronal health markers in Alzheimer's patients, suggesting potential disease-modifying effects for neurodegenerative conditions.
GeoVax to Present COVID-19 Vaccine Data for Immunocompromised Patients at European Vaccine Congress
GeoVax Labs will present interim safety data and special-population insights for its GEO-CM04S1 COVID-19 vaccine at the World Vaccine Congress Europe 2025, highlighting progress in addressing vaccine needs for immunocompromised patients where current options remain insufficient.
Oncotelic's Injectable Everolimus Shows Promise for Dramatically Improved Breast Cancer Treatment
Oncotelic Therapeutics has received clearance to begin Phase 1 clinical trials for Sapu003, an injectable form of Everolimus that could increase drug bioavailability from 10% to up to 100%, potentially transforming breast cancer treatment efficacy.
TransCode Therapeutics Acquires Polynoma, Secures $25 Million Investment to Advance Oncology Pipeline
TransCode Therapeutics has acquired Polynoma and secured $25 million from CK Life Sciences to advance its Phase 2 trial of TTX-MC138 and Phase 3-ready melanoma vaccine seviprotimut-L, positioning the company to deliver meaningful therapeutic advances for patients battling melanoma and metastatic disease.
Oncotelic Therapeutics Announces Phase 1 Trial Enrollment for Novel Intravenous Everolimus Formulation in Australia
Oncotelic Therapeutics has opened enrollment for the first clinical trial of Sapu-003, an intravenous Deciparticle formulation of everolimus that represents a significant advancement in mTOR-targeted cancer therapy delivery for patients with advanced breast cancer and other malignancies.